NCT03184090View on ClinicalTrials.gov

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 28, 2017

Primary Completion Date

October 27, 2020

Study Completion Date

October 27, 2020

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Palbociclib

palbociclib in combination with endocrine therapy (investigator's choice)

DRUG

Endocrine therapy (non IMP)

Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.

Trial Locations (15)

Unknown

Istituto Europeo di Oncologia, Milan

Azienda Sanitaria Universitaria Integrata di Udine, Udine

ICO Badalona, Badalona

Clinico Universitario A Coruña, A Coruña

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Provincial de Castellón, Castellon

Hospital Reina Sofia, Córdoba

Hospital La Paz, Madrid

Hospital Sant Joan de Reus, Reus

Hospital Virgen del Rocío, Seville

Hospital Clinico Universitario de Valencia, Valencia

Hospital Universitari i Politecnic La Fe, Valencia

Instituto Valenciano de Oncología - IVO, Valencia

08007

ICO l'Hospitalet, L'Hospitalet de Llobregat

08003

Hospital del Mar, Barcelona

All Listed Sponsors
lead

MedSIR

OTHER

NCT03184090 - Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ mBC | Biotech Hunter | Biotech Hunter